Patients with heart failure (HF) usually present with skeletal muscle diseases of varying
severity, ranging from early fatigue on exercise to sarcopenia, sarcopenic obesity or …

Increasing evidence has shown that gut microbiota (GM) was involved in the
pathophysiology of musculoskeletal disorders through multiple pathways such as protein …

Background: Epicardial adipose tissue (EAT) accumulation is thought to play a role in the
pathophysiology of heart failure (HF) with mid-range and preserved ejection fraction, but its …

Background Several studies have examined gut microbiota and sarcopenia using 16S
ribosomal RNA amplicon sequencing; however, this technique may not be able to identify …

Background Declined skeletal muscle mass and function are inevitable consequences of
long‐term diabetes and bring about many adverse events. Muscle fibre atrophy and …

Cardiac alterations in structure and function, namely, the left ventricle, have been intensely
studied for decades, in association with aging. In recent times, there has been keen interest …

Exercise intolerance remains a major unmet medical need in patients with heart failure (HF).
Skeletal myopathy is currently considered as the major limiting factor for exercise capacity in …

Heart failure with preserved ejection fraction (HFpEF) is a major clinical problem, with limited
treatments. HFpEF is characterized by a distinct, but poorly understood, skeletal muscle …

BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2
inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters …

This review highlights some established and some more contemporary mechanisms
responsible for heart failure (HF)-induced skeletal muscle wasting and weakness. We first …